How the addition of glucagon receptor activity changes the receptor profile, and where each sits in the current published literature.
At a glance
- Tirzepatide: dual agonist at the GIP and GLP-1 receptors.
- Retatrutide: triple agonist adding glucagon receptor activity to the same two axes.
- The comparison is essentially about what a third receptor adds to an established dual profile.
- Both are supplied lyophilised at ≥99% HPLC purity with batch-matched certificates.
The third receptor
Tirzepatide’s published profile covers incretin signalling through two receptors. Retatrutide extends that to the glucagon receptor, which in the literature is associated with energy-expenditure and hepatic endpoints rather than with the insulinotropic effects that dominate incretin papers.
Adding a receptor does not simply increase a single effect. Published work on triple agonism describes a different overall response pattern, which is why retatrutide is usually treated as a separate class in study design rather than as a stronger version of tirzepatide.
Design considerations
- Control arms: a triple agonist generally requires a dual-agonist arm to attribute any difference to the glucagon component.
- Endpoint selection: hepatic and energy-expenditure endpoints become relevant with retatrutide that may not be captured in a tirzepatide-only design.
- Receptor blockade: selective antagonists are the usual route to separating the three contributions.
- Literature maturity: tirzepatide has the larger published base; retatrutide research is newer and more sparsely documented.
Handling and documentation
Both are acylated long-chain peptides supplied as lyophilised powder. Store sealed at -20°C away from light, warm to room temperature before opening, reconstitute slowly and avoid shaking. Aliquot at reconstitution where a study spans multiple sessions.
Because both are frequently used in comparative work, keep the certificate of analysis for each batch with the study record so purity and identity can be cited alongside results.
Which to select
Where the research question concerns incretin signalling alone, tirzepatide remains the conventional reference. Where the question concerns broader metabolic receptor coverage, retatrutide is the compound the current literature points to — usually alongside tirzepatide rather than instead of it.
Both are laboratory reference materials supplied to qualified research professionals in Ireland. They are not medicines and are not supplied for human or veterinary use.